- Home
- OBIO vs EVC Comparison
OBIO vs EVC Comparison
Compare OBIO & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- EVC
- Stock Information
- Founded
- OBIO 2017
- EVC 1996
- Country
- OBIO United States
- EVC United States
- Employees
- OBIO N/A
- EVC N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- EVC Broadcasting
- Sector
- OBIO Health Care
- EVC Industrials
- Exchange
- OBIO Nasdaq
- EVC Nasdaq
- Market Cap
- OBIO 151.3M
- EVC 179.2M
- IPO Year
- OBIO N/A
- EVC 2000
- Fundamental
- Price
- OBIO $4.28
- EVC $2.11
- Analyst Decision
- OBIO Strong Buy
- EVC
- Analyst Count
- OBIO 5
- EVC 0
- Target Price
- OBIO $15.40
- EVC N/A
- AVG Volume (30 Days)
- OBIO 51.3K
- EVC 486.1K
- Earning Date
- OBIO 05-12-2025
- EVC 03-06-2025
- Dividend Yield
- OBIO N/A
- EVC 9.41%
- EPS Growth
- OBIO N/A
- EVC N/A
- EPS
- OBIO N/A
- EVC N/A
- Revenue
- OBIO $2,647,000.00
- EVC $364,948,000.00
- Revenue This Year
- OBIO $22.61
- EVC $64.06
- Revenue Next Year
- OBIO $16.64
- EVC N/A
- P/E Ratio
- OBIO N/A
- EVC N/A
- Revenue Growth
- OBIO N/A
- EVC 22.86
- 52 Week Low
- OBIO $3.75
- EVC $1.58
- 52 Week High
- OBIO $8.87
- EVC $2.73
- Technical
- Relative Strength Index (RSI)
- OBIO 45.19
- EVC 50.49
- Support Level
- OBIO $4.14
- EVC $2.05
- Resistance Level
- OBIO $4.67
- EVC $2.27
- Average True Range (ATR)
- OBIO 0.34
- EVC 0.12
- MACD
- OBIO 0.06
- EVC 0.02
- Stochastic Oscillator
- OBIO 51.70
- EVC 67.00
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About EVC Entravision Communications Corporation
Entravision Communications Corp is a global advertising solutions, media, and technology company. Its operations encompass integrated marketing and media solutions, comprised of television, radio, and digital properties and data analytics services. The company operates in television broadcasting, audio broadcasting, and digital media segments. The Company's digital segment, whose operations are located in Europe, Latin America, Asia, the United States, and Africa. The Company's television and audio operations reach and engage U.S. Hispanics in the United States.